GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » EV-to-FCF

Solvonis Therapeutics (LSE:SVNS) EV-to-FCF : -3.41 (As of Mar. 30, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Solvonis Therapeutics's Enterprise Value is £2.62 Mil. Solvonis Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.77 Mil. Therefore, Solvonis Therapeutics's EV-to-FCF for today is -3.41.

The historical rank and industry rank for Solvonis Therapeutics's EV-to-FCF or its related term are showing as below:

LSE:SVNS' s EV-to-FCF Range Over the Past 10 Years
Min: -129.92   Med: -0.44   Max: 0.33
Current: -3.65

During the past 6 years, the highest EV-to-FCF of Solvonis Therapeutics was 0.33. The lowest was -129.92. And the median was -0.44.

LSE:SVNS's EV-to-FCF is ranked worse than
100% of 1690 companies
in the Industrial Products industry
Industry Median: 22.35 vs LSE:SVNS: -3.65

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-30), Solvonis Therapeutics's stock price is £0.00155. Solvonis Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.023. Therefore, Solvonis Therapeutics's PE Ratio (TTM) for today is At Loss.


Solvonis Therapeutics EV-to-FCF Historical Data

The historical data trend for Solvonis Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics EV-to-FCF Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - - -4.18 -0.32

Solvonis Therapeutics Semi-Annual Data
May18 May19 May20 May21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only - -4.18 - -0.32 -

Competitive Comparison of Solvonis Therapeutics's EV-to-FCF

For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solvonis Therapeutics's EV-to-FCF Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Solvonis Therapeutics's EV-to-FCF falls into.


;
;

Solvonis Therapeutics EV-to-FCF Calculation

Solvonis Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2.619/-0.767
=-3.41

Solvonis Therapeutics's current Enterprise Value is £2.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Solvonis Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Solvonis Therapeutics  (LSE:SVNS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Solvonis Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00155/-0.023
=At Loss

Solvonis Therapeutics's share price for today is £0.00155.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Solvonis Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.023.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Solvonis Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Solvonis Therapeutics Business Description

Traded in Other Exchanges
Address
Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines